Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer

Overview

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Description

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: prostate cancer
  • Age: - 100 Years
  • Gender: Male or Female
Updated on 20 Nov 2022 . Study ID: TX7906

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center